FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 194 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab MOST POPULAR Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... June 9, 2022 Long-Term Outcomes in Patients with Metastatic Melanoma Treated with Anti-PD1 Therapy... October 28, 2021 Load more HOT NEWS Alex Trebek Has Completed Chemo And Will Be Back For The... Learning to Live With Cancer: A Survivor’s Story Connecting and Celebrating Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than...
